¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Children's Night Time Cold Med Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • recovery time
    ȸº¹½Ã°£
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
  • spin lattice relaxation time
    ½ºÇɰÝÀÚÀ̿Ͻð£
  • spin-spin relaxation time
    ½ºÇɽºÇÉÀ̿Ͻð£
  • survival time
    »ýÁ¸±â°£
  • synaptic time
    ½Ã³À½ºÅë°ú½Ã°£, ¿¬Á¢Åë°ú½Ã°£
  • sedimentation time
    ħ°­½Ã°£
  • sinoatrial conduction time
    ±¼½É¹æÀüµµ½Ã°£, µ¿½É¹æÀüµµ½Ã°£
  • sinus node recovery time
    ±¼°áÀýȸº¹½Ã°£, µ¿°áÀýȸº¹½Ã°£
  • tear film breakup time
    ´«¹°¸·ÆÄ±«½Ã°£
  • utilization time
    ÀÌ¿ë½Ã°£
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • voiding time
    ¹è´¢½Ã°£
  • zero-time shift
    ¿øÁ¡À̵¿
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • perception time
    Áö°¢½Ã°£, ÀνĽð£
  • person-time incidence rate
    »ç¶÷±â°£¹ß»ý·ü
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • polymerizing time
    ±»´Â½Ã°£, ÁßÇսð£
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • reaction time
    ¹ÝÀÀ½Ã°£
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time system
    ½Ç½Ã°£Ã¼°è
  • recirculation time
    Àç¼øÈ¯½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • repetition time
    ¹Ýº¹½Ã°£
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • oral arch
    ÀÔ±Ã, ±¸°³±Ã(Ï¢ËÏÏá).
  • oral atresia ³ª a. oris, atretostomia
    (¼±Ãµ¼º) ±¸°­Æó¼â(Áõ)(à»ô¸àõϢ˷øÍáðñø).
  • oral atresia ³ª a. oris, atretostomia
    (¼±Ãµ¼º) ±¸°­Æó¼â(Áõ)((à»ô¸àõ) Ϣ˷øÍáð(ñø))
  • oral bacteria
    ±¸°­¼¼±Õ
  • oral bacteria
    ±¸°­¼¼±Õ(Ϣ˷á¬Ð¶).
  • oral bacteriology
    ±¸°­¼¼±ÕÇÐ(Ϣ˷á¬Ð¶ùÊ).
  • oral bacterium
    ±¸°­¼¼±Õ(Ϣ˷á¬Ð¶).
  • oral bay
    °Å»ó¿¬¸¸
  • oral behavior
    ±¸°­¼º Çൿ
  • oral cancer
    ±¸°­¾Ï
  • oral cancer
    ±¸°­¾Ï(Ϣ˷ ).
  • oral cancer
    ±¸°­¾Ï(Ϣ˷äß)
  • oral candidiasis
    ±¸°­Ä­µð´ÙÁõ, ±¸°­¹é¹Ýâ
  • oral cavity
    ±¸°­
  • oral cavity
    ÀÔ¾È (±¸°­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
ACU acquired cold urticaria; acute care unit; agar colony-forming unit; ambulatory care unit
CA anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can...
CAD cadaver, cadaveric; cold agglutinin disease; compressed air disease; computer-assisted design; compu...
CAS calcarine sulcus; calcific aortic stenosis; Cancer Attitude Survey; carbohydrate-active steroid; car...
CC calcaneal-cuboid; calcium cyclamate; cardiac catheterization; cardiac contusion; cardiac cycle; card...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
S-CHIP State Children's Health Insurance Program
STAIC State-Trait Anxiety Inventory for Children
UKCCSG United Kingdom Children Cancer Study Group
UNICEF United Nations Children's Found
VFC Vaccine for Children
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • oral-facial-digital syndrome, type I
    IÇü±¸-¾È¸é-ÁöÁõÈıº
    X-¿¬°ü¼º ¿ì¼º À¯Àüº´À¸·Î¼­ ³²ÀÚ¿¡°Ô´Â Ä¡¸íÀûÀ¸·Î ±¼ÁöÁõ, ´ÙÁöÁõ, ÇÕÁöÁõ µîÀÌ Æ¯Â¡À̸ç, µÎ°³, ¾È¸é, ¼³, ±¸°³ ¹× ÇÏ¾Ç ±âÇüÀ» ¼ö¹ÝÇϰųª Áö´É ÀúÇÏ, Å»¸ðÁõ, ¾È¸é Áö·ç¸¦ ¼ö¹ÝÇÑ´Ù.
  • recurring oral ulcer
    Àç¹ß¼º ±¸°­ ±Ë¾ç
  • simplified oral hygiene index
    ´Ü¼ø ±¸°­ À§»ý Áö¼ö
  • The Amirican Association of Oral andMaxillofacial Surgeons
    ¹Ì±¹ ±¸°­ ¹× ¾Ç¾È¸é¿Ü°úÇùȸ
  • verrucous oral lesion
    ¿ìÃé»ó ±¸°­ º´¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
P-A conduction time See: atrioventricular conduction.
(05 Mar 2000)
generation time <cell biology> Time taken for a cell population to double in numbers and thus equivalent to the average length of the cell cycle.
(18 Nov 1997)
reaction time The time from the onset of a stimulus until the organism responds.
(12 Dec 1998)
real-time ultrasonography Rapid serial ultrasound images produced using a phased array or scanning transducer; produces a video display of organ motion, such as heart valve or foetal motion.
(05 Mar 2000)
recognition time The interval between the application of a stimulus and the recognition of its nature.
(05 Mar 2000)
partial thromboplastin time Test of the intrinsic (factors viii, ix, xi, and xii) and common (fibrinogen, prothrombin, factors v and x) pathways of coagulation in which a mixture of plasma and phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides) is recalcified and the time required for the appearance of fibrin strands measured. Activation may be provided by contact with the glass tube or exposure to activators (e.g., ellagic acid, particulate silicates such as diatomaceous earth or kaolin) before addition of the calcium chloride. It is used as a screening test and to monitor heparin therapy.
(12 Dec 1998)
relaxation time Time taken for a system to return to the resting or ground state or a new equilibrium state following perturbation. Often used in context of receptor systems that have a refractory period after responding and then relax to a competent state. Can be used more precisely to mean the time for a system to change from its original equilibrium value to 1/e of this original value.
(18 Nov 1997)
median time to elimination <pharmacology> The time it takes one half of a drug to be eliminated from the body.
(09 Oct 1997)
repetition time In magnetic resonance imaging, the time between repetitions of the pulse sequence.
(05 Mar 2000)
rise time The time required for a pulse or echo to rise from 10% to 90% of its peak amplitude.
(05 Mar 2000)
P-H conduction time See: atrioventricular conduction.
(05 Mar 2000)
running time The time during which an activity (e.g., chromatography development) occurs.
(05 Mar 2000)
Russell's viper venom clotting time A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects.
See: Stypven time test.
(05 Mar 2000)
circulation time The time taken for the blood to pass through a given circuit of the vascular system, e.g., the pulmonary or systemic circulation, from one arm to another, from arm to tongue, or from arm to lung; it is measured by the injection into an arm vein of a substance, such as sodium dehydrocholate, ether, fluorescein, histamine, or a radium salt, which can be detected when it arrives at another point in the vascular system.
(05 Mar 2000)
clot retraction time The time required for a blood clot to separate from the tube wall and express serum, usually completed in 18 to 24 hours, but retarded or absent in persons with thrombocytopenic purpura.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • time
    ½Ã°£,°èÀý,(º¹¼ö)½Ã´ë,-ȸ(¹è)
  • Central (Standard) Time
    ÁߺΠǥÁؽÃ(G.M.T.º¸´Ù 6½Ã°£ ´ÊÀ½)
  • Double Summer Time
    ÀÌÁß ¼­¸ÓŸÀÓ(Ç¥Áؽ𣺸´Ù 2½Ã°£ ºü¸§)
  • Eastern Standard time
    µ¿ºÎ Ç¥ÁؽÃ(ij³ª´Ù µ¿ºÎ,¹Ì±¹ µ¿ºÎ,¿À½ºÆ®·¹Àϸ®¾Æ µ¿¹«)
  • Father Time
    ½Ã°£ ÇҾƹöÁö
  • Greenwich (Mean(Civil)time
    ±×¸®´ÏÄ¡ Ç¥ÁؽÃ
  • Greenwich Mean Time
    ±×¸®´ÏÄ¡ Ç¥ÁؽÃ
  • Hawaii time
    =Hawaiian Standard TimeÇÏ¿ÍÀÌ Ç¥ÁؽÃ(GMEº¸´Ù 10½Ã°£ ´Ê°í ½Ã°£´ë´Â Alaska Time¿Í °°À½
  • Pacific(Standard) Time
    (¹Ì±¹ÀÇ) ÅÂÆò¾ç Ç¥ÁؽÃ
  • T-time
    ·ÎÄÏ ¹ß»ç ½Ã°£
  • Time Square
    New York ½ÃÀDZØÀå°¡
  • access time
    È£Ãâ½Ã°£(±â¾ï ÀåÄ¡¿¡ Á¤º¸¸¦ ±â·Ï,ÇØµ¶ÄÉ Çϱâ À§ÇÑ ½Ã°£);ÄÄÇ»ÅÍ¿ë¾î
  • apparent time
    (ÇØ½Ã°èµîÀÇ)žçÀÇ À§Ä¡·Î ÃøÁ¤Çϴ½ð£
  • atomic time clock
    ¿øÀÚ ¿¬´ë ½Ã°è
  • atonic time clock
    ¿øÀÚ¿¬´ë
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á